CardioMEMS PA Pressure Monitoring — EECC MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: D — The CardioMEMS HF System (implantable pulmonary artery pressure sensor) enables daily haemodynamic-guided management — the CHAMPION and MONITOR-HF trials showed 28-44% reduction in HF hospitalisations through proactive diuretic adjustment based on daily PA pressure readings
The CardioMEMS HF System is a wireless implantable pulmonary artery pressure sensor that transmits daily haemodynamic data. Clinical evidence: (1) CHAMPION trial: 28% reduction in HF hospitalisations over 6 months; sustained benefit at 18 months; (2) MONITOR-HF trial: 44% reduction in HF hospitalisations; improved quality of life and NT-proBNP. Mechanism of benefit: elevated PA pressures precede symptoms and weight gain by days-weeks; early detection enables proactive diuretic adjustment (increasing diuretic before clinical decompensation). The 2023 ESC HF Guidelines include PA pressure-guided management as Class IIb for NYHA III patients with prior HF hospitalisation. The device is implanted percutaneously (via femoral vein, like an RHC), is MRI-conditional, has no battery (powered wirelessly during daily readings), and lasts indefinitely. Emerging devices include LA pressure sensors and multiparameter monitors.
Reference: ESC (2023): HF Guidelines; CHAMPION/MONITOR-HF Trials